In the last few years, there has been a rise in the use of controlled ovarian stimulation with aromatase inhibitors (i.e., letrozole) for fertility preservation, especially among women with a diagnosis of breast (or other) cancer prior to the initiation of chemotherapy [20]. This evidence concerns the gene CYP19A1 and cancer.